DUBLIN, Ohio, July 19 /PRNewswire-FirstCall/ -- Cardinal Health, a
global provider of products and services that improve the safety and
productivity of health care, today announced an exclusive, four-year
distribution agreement with HemCon Medical Technologies, Inc. to provide
its new line of hemorrhage control bandages to hospitals, surgery centers
and physician offices in the United States.
HemCon(R) Bandages, used by the U.S. military since 2003, have
demonstrated a 97% effective rate in controlling bleeding on the
battlefield (1). HemCon recently reengineered its bandages to meet the
specific needs of civilian trauma and emergency medicine. The new bandages,
which control severe arterial bleeding, are thinner, more flexible and
sized differently than the original HemCon military bandage. The technology
used in the bandages is particularly useful in hospital settings, because
it allows providers to standardize one hemorrhage control solution across
"The U.S. military has used our bandages to save soldiers' lives for
years, so we're excited to now form this exclusive partnership with
Cardinal Health to bring this life-saving technology to the United States
civilian sector as well," said John W. Morgan, president and CEO of HemCon
Medical Technologies, Inc. "Cardinal Health's extensive clinical expertise
and strong hospital relationships made it the ideal partner to bring
HemCon's innovative technology to the U.S. health-care market. This
partnership will allow a higher standard of care that will benefit both
clinicians and patients."
Using Chitosan, an extract from shrimp shells, the HemCon(R) Bandage
controls moderate to severe external bleeding within minutes of being
applied directly to moderate- or high-pressure, high-flow external bleeds.
It aggressively adheres to the site when it contacts blood or moisture.
This adhesive-like action forms a strong, flexible barrier that seals and
stabilizes the wound.
"Uncontrolled bleeding is the second leading cause of death in the
United States, after trauma (2), and more than six million bleeding wounds
are treated annually by trauma and emergency rooms in the U.S. (3)," said
Mike Kaufmann, president of Healthcare Supply Chain Services-Medical for
Cardinal Health. "That's just one reason why we are thrilled to have the
exclusive opportunity to bring this life-saving product to health-care
providers throughout the United States. This partnership is a perfect
example of Cardinal Health's commitment to delivering innovative products
that improve patient outcomes."
By directly controlling blood loss, even in the case of severed
arterial bleeds, HemCon(R) Bandages reduce the need for transfusions and
provide critical time to administer care (up to 48 hours from the point of
HemCon's new bandages are available in a variety of sizes, have a
three- year shelf life and are latex-free. These sizes were chosen to
specifically address the wounds seen in civilian emergency and trauma cases
such as lacerations, knife injuries, motor vehicle accidents and gunshot
wounds. In addition to being useful in the emergency room, HemCon Bandages
are also useful in cardiac catheterization and interventional radiology
The products will be co-labeled by HemCon and Cardinal Health, and will
be available through Cardinal Health hospital supply distribution and in
Presource(R) kits and trays. For product information, Cardinal Health
customers should contact their hospital supply sales representative.
Information is also available by calling Cardinal Health at 847-689-6459.
About HemCon Medical Technologies, Inc.
HemCon Medical Technologies Inc., founded in 2001, develops,
manufactures, and markets innovative technologies to control bleeding and
infection resulting from trauma or surgery. HemCon products are designed
for use by military and civilian first responders as well as medical
professionals in hospital, dental and clinical settings where rapid control
of bleeding is of critical importance. HemCon's manufacturing and corporate
headquarters are located in Portland, Oregon. To learn more, visit
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an
$80 billion, global company serving the health-care industry with products
and services that help hospitals, physician offices and pharmacies reduce
costs, improve safety, productivity and profitability, and deliver better
care to patients. With a focus on making supply chains more efficient,
reducing hospital-acquired infections and breaking the cycle of harmful
medication errors, Cardinal Health develops market-leading technologies,
including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems,
MedMined(R) data mining software and the CareFusion(TM) patient
identification system. The company also manufactures medical and surgical
products and is one of the largest distributors of pharmaceuticals and
medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in
its sector on Fortune's ranking of Most Admired firms, Cardinal Health
employs more than 40,000 people on five continents. More information about
the company may be found at http://www.cardinalhealth.com.
Except for historical information, all other information in this news
release consists of forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. These
forward- looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected,
anticipated or implied. The most significant of these uncertainties are
described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports
(including all amendments to those reports) and exhibits to those reports,
and include (but are not limited to) the following: competitive pressures
in its various lines of business; the loss of one or more key customer or
supplier relationships or changes to the terms of those relationships;
changes in the distribution patterns or reimbursement rates for health-care
products and/or services; the results, consequences, effects or timing of
any inquiry or investigation by any regulatory authority or any legal and
administrative proceedings; difficulties, delays or additional costs in
implementing the company's global restructuring program; and general
economic and market conditions. Except to the extent required by applicable
law, Cardinal Health undertakes no obligation to update or revise any
(1) Wedmore, Ian, John G. McManus, Anthony E. Pusateri, and John B.
Holcomb. "A Special Report on the Chitosan-based Hemostatic Dressing:
Experience in Current Combat Operations." Journal of Trauma: Injury,
Infection and Critical Care 60.3 (2006) : 655 - 658.
(2) Sauaia, A., Moore, F. A., Moore, E. E., et al. (1995). Epidemiology
of trauma deaths: a reassessment. J Trauma, 38,185-193.
(3) National Hospital Ambulatory Medical Care Survey: 2004 Emergency
Department Summary, Centers for Disease Control, 2004 Report.
SOURCE Cardinal Health Inc.